Treatment of advanced small cell lung cancer. Clinical case and literature review

Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung...

Full description

Bibliographic Details
Main Authors: Konstantin V. Menshikov, Aleksandr V. Sultanbaev, Shamil I. Musin, Irina A. Menshikova, Ainur F. Nasretdinov, Nadezda I. Sultanbaeva
Format: Article
Language:Russian
Published: IP Habib O.N. 2021-05-01
Series:Современная онкология
Subjects:
Online Access:https://modernonco.orscience.ru/1815-1434/article/viewFile/70357/51291
_version_ 1819039524822450176
author Konstantin V. Menshikov
Aleksandr V. Sultanbaev
Shamil I. Musin
Irina A. Menshikova
Ainur F. Nasretdinov
Nadezda I. Sultanbaeva
author_facet Konstantin V. Menshikov
Aleksandr V. Sultanbaev
Shamil I. Musin
Irina A. Menshikova
Ainur F. Nasretdinov
Nadezda I. Sultanbaeva
author_sort Konstantin V. Menshikov
collection DOAJ
description Lung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung cancer (SCLC) is one of the most prognostically unfavorable malignant tumors in humans. About 15% of lung tumors are SCLC. The first combination for the treatment of advanced SCLC after etoposide and platinum preparations was the combination of the etoposide + carboplatin (EP) regimen with atezolizumab. In the IMpower133 study, after a median follow-up of 13.9 months. median overall survival in the atezolizumab group was 12.3 months, and in the placebo group 10.3 months. In clinical observation, the effectiveness of the combination of the EP regimen with atezolizumab has been demonstrated. A patient with SCLC received 4 courses of EP therapy with atezolizumab and 14 injections of atezolizumab. The partial response achieved is retained. Case study efficacy and satisfactory safety profile of the combination of atezolizumab and the EP regimen.
first_indexed 2024-12-21T08:54:35Z
format Article
id doaj.art-84b8fb205d4b4a0d9e375fb79bab01f4
institution Directory Open Access Journal
issn 1815-1434
1815-1442
language Russian
last_indexed 2024-12-21T08:54:35Z
publishDate 2021-05-01
publisher IP Habib O.N.
record_format Article
series Современная онкология
spelling doaj.art-84b8fb205d4b4a0d9e375fb79bab01f42022-12-21T19:09:36ZrusIP Habib O.N.Современная онкология1815-14341815-14422021-05-0123111211510.26442/18151434.2021.1.20072664570Treatment of advanced small cell lung cancer. Clinical case and literature reviewKonstantin V. Menshikov0https://orcid.org/0000-0003-3734-2779Aleksandr V. Sultanbaev1https://orcid.org/0000-0003-0996-5995Shamil I. Musin2https://orcid.org/0000-0003-1185-977XIrina A. Menshikova3https://orcid.org/0000-0002-8665-8895Ainur F. Nasretdinov4https://orcid.org/0000-0001-8340-7962Nadezda I. Sultanbaeva5https://orcid.org/0000-0001-5926-0446Republican Clinical Oncological DispensaryRepublican Clinical Oncological DispensaryRepublican Clinical Oncological DispensaryBashkir State Medical UniversityRepublican Clinical Oncological DispensaryRepublican Clinical Oncological DispensaryLung cancer is one of the most common tumors in humans. The incidence is in one of the leading positions. In 2019 1327 patients with this pathology were identified in the Republic of Bashkortostan. Of these, with stage III of the disease 28.7%, with stage IV 45.8%, which is higher. Small cell lung cancer (SCLC) is one of the most prognostically unfavorable malignant tumors in humans. About 15% of lung tumors are SCLC. The first combination for the treatment of advanced SCLC after etoposide and platinum preparations was the combination of the etoposide + carboplatin (EP) regimen with atezolizumab. In the IMpower133 study, after a median follow-up of 13.9 months. median overall survival in the atezolizumab group was 12.3 months, and in the placebo group 10.3 months. In clinical observation, the effectiveness of the combination of the EP regimen with atezolizumab has been demonstrated. A patient with SCLC received 4 courses of EP therapy with atezolizumab and 14 injections of atezolizumab. The partial response achieved is retained. Case study efficacy and satisfactory safety profile of the combination of atezolizumab and the EP regimen.https://modernonco.orscience.ru/1815-1434/article/viewFile/70357/51291small cell lung cancerimmunotherapychemotherapyatezolizumabimpower133overall survival
spellingShingle Konstantin V. Menshikov
Aleksandr V. Sultanbaev
Shamil I. Musin
Irina A. Menshikova
Ainur F. Nasretdinov
Nadezda I. Sultanbaeva
Treatment of advanced small cell lung cancer. Clinical case and literature review
Современная онкология
small cell lung cancer
immunotherapy
chemotherapy
atezolizumab
impower133
overall survival
title Treatment of advanced small cell lung cancer. Clinical case and literature review
title_full Treatment of advanced small cell lung cancer. Clinical case and literature review
title_fullStr Treatment of advanced small cell lung cancer. Clinical case and literature review
title_full_unstemmed Treatment of advanced small cell lung cancer. Clinical case and literature review
title_short Treatment of advanced small cell lung cancer. Clinical case and literature review
title_sort treatment of advanced small cell lung cancer clinical case and literature review
topic small cell lung cancer
immunotherapy
chemotherapy
atezolizumab
impower133
overall survival
url https://modernonco.orscience.ru/1815-1434/article/viewFile/70357/51291
work_keys_str_mv AT konstantinvmenshikov treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview
AT aleksandrvsultanbaev treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview
AT shamilimusin treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview
AT irinaamenshikova treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview
AT ainurfnasretdinov treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview
AT nadezdaisultanbaeva treatmentofadvancedsmallcelllungcancerclinicalcaseandliteraturereview